Ganirelix Acetate

Ganirelix Acetate Struktur
123246-29-7
CAS-Nr.
123246-29-7
Englisch Name:
Ganirelix Acetate
Synonyma:
GANIRELIX;Ganirelixum;5-?dihydroxy-;3-?bis[[3-?(3;ganirelix Acetate;Ganirelix DiAcetate;Ganirelix Impurity 1;Ganirelix Acetate API;Ganirelix Acetate USP/EP/BP;4-?dihydroxyphenyl)?-?1-?oxo-?2-?propen-?1-?yl]?oxy]?-?4
CBNumber:
CB61370494
Summenformel:
C80H113ClN18O13
Molgewicht:
1570.34
MOL-Datei:
123246-29-7.mol

Ganirelix Acetate Eigenschaften

Sequenz
Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-Tyr-D-Har(Et2)-Leu-Har(Et2)-Pro-DAla-NH2
InChIKey
GJNXBNATEDXMAK-HJHIFQDRNA-N

Sicherheit

HS Code  3504009000

Ganirelix Acetate Chemische Eigenschaften,Einsatz,Produktion Methoden

Originator

Antagon,Organon

Therapeutic Function

LHRH antagonist

Clinical Use

Ganirelix acetate is an analog of GnRH with substitutions at residues 1, 2, 3, 6, 8, and 10. It is not a superagonist but, rather, is a synthetic decapeptide with high antagonist activity and the first GnRH antagonist to be marketed. It is approved for the suppression of LH surges in women who are undergoing ovarian hyperstimulation fertility treatment; LH surges normally promote ovulation. The goal of this drug is to significantly reduce the number of medication days necessary to suppress the LH surge, thereby maintaining eggs in the ovaries. In vitro fertilization (IVF) treatment cycles were historically initiated by the administration of leuprolide acetate to suppress the premature release of LH. This inhibits ovulation so that the eggs remain available for retrieval by a fertility specialist. For this purpose, leuprolide acetate usually is injected for as many as 26 days. Clinical studies have shown that ganirelix acetate can shut down the LH surge in only 5 days of treatment, that the suppression of LH is more pronounced than that of FSH, and that the shorter treatment time minimizes unpleasant side effects, such as hot flashes and headaches.

Ganirelix Acetate Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Ganirelix Acetate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 225)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shanghai Affida new material science and technology center
+undefined15081010295
admin@oudaxin.com China 114 58
Shaanxi TNJONE Pharmaceutical Co., Ltd
+8618092446649
sarah@tnjone.com China 1143 58
Chongqing Soarwin Technology Co., Ltd
+86-15790943001
crystal@sorawin.cn China 421 58
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
+86-15225627621 +86-13213167925
jiuyitime@fdachem.com China 16512 58
Adachibio Inc.
+81-8027837258; +8108027837258
sales@adachibio.com Japan 938 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21586 55
Shenzhen Nexconn Pharmatechs Ltd
+86-755-89396905 +86-15013857715
admin@nexconn.com China 10403 58
Shanghai Longyu Biotechnology Co., Ltd.

info@longyupharma.com China 2421 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49979 58
career henan chemical co
+86-0371-86658258 +8613203830695
factory@coreychem.com China 29792 58

123246-29-7()Verwandte Suche:


  • Ac-DNal-DCpa-DPal-Ser-Tyr-DHar(Et2)-Leu-Har(Et2)-Pro-DAla -NH2
  • Ganirelixum
  • ganirelix Acetate
  • Ganirelix Acetate USP/EP/BP
  • Ganirelix Impurity 1
  • Ganirelix Acetate API
  • 3-?bis[[3-?(3
  • 4-?dihydroxyphenyl)?-?1-?oxo-?2-?propen-?1-?yl]?oxy]?-?4
  • 5-?dihydroxy-
  • Ganirelix DiAcetate
  • GANIRELIX
  • 123246-29-7
  • 23246-29-7
  • C80H113ClN18O13
  • hormones
Copyright 2019 © ChemicalBook. All rights reserved